{"id":"NCT00487435","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain","officialTitle":"Open-Label Extension, Single-Arm, Flexible-Dosing, Phase 3 Trial With CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2007-06-18","resultsPosted":"2010-07-23","lastUpdate":"2014-05-09"},"enrollment":1166,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain","Osteoarthritis","Low Back Pain"],"interventions":[{"type":"DRUG","name":"Tapentadol (CG5503) Extended Release (ER)","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a period of 1 year. The study will also assess dosage requirements over the long term; characterize adverse events and tolerability, sleep quality, and potential symptoms of withdrawal; characterize pain intensity scores and overall impression of change; and characterize patient-related health outcomes.","primaryOutcome":{"measure":"Number of Subjects With Treatment-emergent Adverse Events (TEAE)","timeFrame":"52 weeks","effectByArm":[{"arm":"Tapentadol (CG5503) Extended Release (ER)","deltaMin":907,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":148,"countries":["United States","Australia","Canada","New Zealand"]},"refs":{"pmids":["26428249"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=70&filename=CR013567_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":84,"n":1154},"commonTop":["Headache","Nausea","Constipation","Diarrhoea","Insomnia"]}}